Loren Data's SAM Daily™

FBO DAILY ISSUE OF AUGUST 15, 2002 FBO #0256
SOLICITATION NOTICE

A -- Gene Sequencing

Notice Date

8/13/2002
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-20104-NG
 

Response Due

8/28/2002
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 

E-Mail Address

holdcram@exchange.nih.gov, cr214i@nih.gov
 

Description

The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) Clinical Genetics Branch (CGB) plans to procure BRCA1/BRCA2 GENE SEQUENCING services with Myriad Genetic Laboratories, Inc., 320 Wakara Way, Salt Lake City, Utah 84108. The supplies and services herein are commercial as defined in FAR Part 12, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items as authorized in FAR Part 13.5. The North American Industry Classification System code is 541710 and the business size standard is 500 employees. The Clinical Genetics Branch (CGB) is engaged in an ongoing clinical genetics study of hereditary breast/ovarian cancer. CGB has a need to obtain complete sequencing of the two-breast/ovarian cancer susceptibility genes known as BRCA1 and BRCA2 as part of this research project. In addition, the CGB has a need for mutation testing, which targets the three Ashkenazi founder BRCA mutations, and for single mutation testing in either BRCA1 or BRCA2 in selected individuals. The samples were derived from individuals who are members of families in which these two cancers have occurred with unusual frequency. This study is part of a comprehensive, multidisciplinary, intramural research program within DCEG=s Human Genetics Program, which is focused upon elucidation of the entire spectrum of scientific and clinical issues related to familial and hereditary forms of cancer. The current acquisition represents an extension of prior work done for the Government by Myriad Genetics, under purchase order number 263MQ004385 through which CGB submitted 80 DNA samples to Myriad Genetics for germline BRCA1/2 mutation testing. The CGB has decided to expand the scope of this project beyond that originally envisioned. Period of Performance: Upon award of purchase order through twelve (12) months, with four (4) twelve (12) month option renewals if exercised; FAR Clause 52.217-8 Option to extend service (November 1999) and FAR Clause 52.217-9 Option to Extend the Term of the Contract (March 2000) applies to this order. Approximately 40 samples are projected for analysis during each of these time periods. The requirement will be a fixed price order. Myriad Genetic Laboratories, Inc. is the only source known to the NCI that can provide the above service. It is essential to the ongoing scientific integrity and validity of the research studies being supported to obtain future data in a manner which will permit reliable comparison with assay results already obtained. In order to insure comparability of subsequent assay results with those already performed, the current procurement is proposed as a sole source acquisition. Failure to do so could invalidate the cornerstone of these important research projects, i.e., the accurate, timely and reliable classification of study participants with regard to their BRCA1/2 germline mutation status. Myriad Genetics owns the patents on both the BRCA1 and the BRCA2 genes, and thus is the only commercial vendor available to perform the required work. This is not a request for competitive quotations. However, if any interested party believes it can provide the above supplies, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EDT (local Washington D.C. time) on August 28, 2002. If you have questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@excange.nih.gov or by fax at (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
 

Place of Performance

Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD

Zip Code: 20892

Country: USA
 

Record

SN00139406-W 20020815/020813213225 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |